Literature DB >> 16342661

Chronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment.

Farhad Ravandi1, Susan O'Brien.   

Abstract

The World Health Organization classification divides lymphoid malignancies into precursor B-cell and T-cell neoplasms as well as mature B-cell and T-cell neoplasms. Mature B-cell neoplasms comprise more than 85% of non-Hodgkin lymphomas worldwide and can be further subclassified according to the postulated cell of origin by using specific morphologic, immunophenotypic, and molecular characteristics. Similarly, the more uncommon mature T-cell neoplasms have been better characterized to include numerous distinct entities with widely varying natural histories. The distinction between lymphoma and leukemia is somewhat arbitrary and is based on variable involvement of the bone marrow, peripheral blood, and lymphatic system. In this article, we review the diagnostic and clinical features of mature B-cell and T-cell lymphoproliferative disorders that commonly have a leukemic presentation.

Entities:  

Mesh:

Year:  2005        PMID: 16342661     DOI: 10.4065/80.12.1660

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  6 in total

Review 1.  Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.

Authors:  Philipp B Staber; Marco Herling; Mar Bellido; Eric D Jacobsen; Matthew S Davids; Tapan Mahendra Kadia; Andrei Shustov; Olivier Tournilhac; Emmanuel Bachy; Francesco Zaja; Kimmo Porkka; Gregor Hoermann; Ingrid Simonitsch-Klupp; Claudia Haferlach; Stefan Kubicek; Marius E Mayerhoefer; Georg Hopfinger; Ulrich Jaeger; Claire Dearden
Journal:  Blood       Date:  2019-07-10       Impact factor: 22.113

2.  Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies.

Authors:  Kensei Tobinai; Michinori Ogura; Kenichi Ishizawa; Tatsuya Suzuki; Wataru Munakata; Toshiki Uchida; Tomohiro Aoki; Takanobu Morishita; Yoko Ushijima; Satoko Takahara
Journal:  Int J Hematol       Date:  2015-11-20       Impact factor: 2.490

3.  Sequential Kinase Inhibition (Idelalisib/Ibrutinib) Induces Clinical Remission in B-Cell Prolymphocytic Leukemia Harboring a 17p Deletion.

Authors:  H Coelho; M Badior; T Melo
Journal:  Case Rep Hematol       Date:  2017-07-27

4.  B-cell Prolymphocytic Leukemia: Case Report and Challenges on a Diagnostic and Therapeutic Forefront.

Authors:  Bikramjit S Bindra; Harpreet Kaur; Shellsea Portillo; Oluwadunni Emiloju; Katherine Garcia de de Jesus
Journal:  Cureus       Date:  2019-09-11

5.  Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax.

Authors:  Maria Tariq Siddiqui; Allyson Price; Alessandra Ferrajoli; Gautam Borthakur
Journal:  Leuk Res Rep       Date:  2021-08-30

6.  De novo chronic lymphocytic leukemia/prolymphocytic leukemia or B-cell prolymphocytic leukemia? The importance of integrating clinico-morphological and immunophenotypic findings in distinguishing chronic lymphoproliferative diseases with circulating phase.

Authors:  Zachariah Chowdhury; Yookarin Khonglah; Susmita Sarma; Pranjal Kalita
Journal:  Autops Case Rep       Date:  2020-12-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.